BioSpace News Archive

Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference.

February 14, 2022

·

6 min read

FDA

Motus GI Receives FDA Clearance to Market the Pure-Vu® EVS System

Motus GI Holdings, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the Pure-Vu® EVS System.

February 14, 2022

·

5 min read

Biotech Bay

Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors

Fluidigm Corporation (Nasdaq:FLDM) today filed with the U.S. Securities and Exchange Commission to consider and vote upon various items related to the proposed and previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC.

February 14, 2022

·

10 min read

BioMidwest

UAT Group Subsidiary, Ossifix Orthopedics, Begins Production of Fixation Pin, Significant Sales Expected

Umbra Applied Technologies Group, Inc, announced that it has begun fulfilling purchase orders and contracts for orthopedic distributors and clients nationwide.

February 14, 2022

·

4 min read

Business

Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update

Roivant today reported its financial results for the third fiscal quarter ended December 31, 2021 and provided an update on the Company’s operations.

February 14, 2022

·

17 min read

Biotech Bay

Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23

Second Genome today announced that it will host a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator inhibitor (PAI)-1/2 in inflammatory bowel disease (IBD) on Wednesday, February 23, 2022, from 12:00 – 1:00 p.m. EST.

February 14, 2022

·

3 min read

Business

Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea

Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. (NYSE: PFE), today announced positive top-line results from an Asia-Pacific, Phase 3 clinical trial of rimegepant in 1,431 adults for the acute treatment of migraine.

February 14, 2022

·

12 min read

Business

Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022

Castle Biosciences, Inc. today announced that it will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022.

February 14, 2022

·

2 min read

Business

Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results

Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended December 31, 2021.

February 14, 2022

·

5 min read

Policy

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners Inc., a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced that Health Canada has approved the amendment to the CATCO protocol to include its lead drug candidate, LSALT Peptide in a new dosing arm of the trial.

February 14, 2022

·

7 min read